we have lot of news coming out with the fed, bank of england, mof -- i'm sorry, ecb, jobs report. we have a lot of things, and i do believe the market's being a little casual, maybe even naive about what could happen. i'm not calling for a crash, i'm just saying we have a lot of information, and we just don't know what's going to happen by the end of the week. david: p be e for the s&p going forward is still not overvalued, so people say there could be room for growth. >> yeah. david: larry, thank you very much. pharmaceuticals, we haven't talked about them today. two big giants reported earning3 earlier. let's head back to nicole petallides on the floor of the new york stock exchange. how did they fare, nicole? >> both are dow components, two huge names in big pharma, pfizer a winner, up about half a percent, merck down about a half a percent. both companies have tried to keep their costs down for marketing and such, but also they both have the same situation which is generic competition. having the patents expire. merck, for example, for singulare lost 80% of sales because of th